TELMISARTAN AND AMLODIPINE
Clinical safety rating: avoid
NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Use in pregnancy can cause injury and death to the developing fetus.
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx across vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and reduced blood pressure.
| Metabolism | Telmisartan is primarily metabolized by glucuronidation; minor metabolism by CYP2C9. Amlodipine is extensively metabolized by CYP3A4. |
| Excretion | Telmisartan: primarily excreted unchanged in feces (97%) via biliary elimination; renal excretion accounts for <2%. Amlodipine: extensively metabolized in liver; 60% of metabolites excreted renally, 20-25% in feces. Unchanged amlodipine in urine: <10%. |
| Half-life | Telmisartan: terminal half-life ~24 hours (range 20-30 hours), supporting once-daily dosing. Amlodipine: terminal half-life ~30-50 hours (mean 35 hours), achieving steady state after 7-8 days; prolonged half-life allows once-daily dosing. |
| Protein binding | Telmisartan: >99.5% bound to albumin and alpha-1-acid glycoprotein. Amlodipine: approximately 93-98% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Telmisartan: Vd ~500 L (not weight-based; large distribution into tissues). Amlodipine: Vd ~21 L/kg (extensive distribution, high tissue binding). |
| Bioavailability | Telmisartan: oral absolute bioavailability 42-58% (dose-dependent; lower with higher doses). Amlodipine: oral bioavailability 64-90% (mean 64%). |
| Onset of Action | Oral: antihypertensive effect begins within 2 hours for both components. Peak effect for telmisartan at 3-6 hours; amlodipine peak effect at 6-12 hours. |
| Duration of Action | Duration of antihypertensive effect: 24 hours for both components, enabling once-daily dosing. Clinical notes: consistent blood pressure reduction over 24 h, with trough-to-peak ratio >0.8 for amlodipine. |
| Molecular Weight | Telmisartan: 514.62 Da; Amlodipine: 408.88 Da (as base) or 567.1 Da (besylate salt). Combined product not a single entity. |
Oral: one tablet containing telmisartan 40-80 mg and amlodipine 5-10 mg once daily; maximum dose: telmisartan 80 mg/amlodipine 10 mg daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR >30 mL/min. For GFR <30 mL/min, use with caution; no specific dose adjustment guidelines; monitor serum potassium and creatinine. |
| Liver impairment | Child-Pugh A: maximum amlodipine dose 5 mg daily; Child-Pugh B: initiate amlodipine at 2.5 mg daily, titrate slowly; Child-Pugh C: contraindicated; telmisartan dose adjustment not specified, but caution advised. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no specific dosing guidelines. |
| Geriatric use | Initiate therapy with lowest available dose (telmisartan 40 mg/amlodipine 5 mg); titrate slowly; monitor for hypotension and electrolyte disturbances; patients >75 years may require lower starting doses. |
| 1st trimester | Avoid: Drugs acting on the renin-angiotensin system (telmisartan) are associated with fetal renal dysplasia, oligohydramnios, and skull ossification defects; amlodipine may cause fetal hypoxia. |
| 2nd trimester | Contraindicated: Telmisartan causes fetal nephrotoxicity and oligohydramnios; amlodipine may impair uteroplacental perfusion. |
| 3rd trimester | Contraindicated: High risk of neonatal renal failure, oligohydramnios, hypotension, and hyperkalemia; amlodipine may prolong labor. |
Clinical note
NSAIDs may diminish the antihypertensive effect Lithium levels may be increased Use in pregnancy can cause injury and death to the developing fetus.
| FDA category | Contraindicated |
| Placental transfer | Both drugs cross the placenta. Telmisartan: known human placental transfer via RAS interaction. Amlodipine: animal studies show placental transfer; human data limited but expected. |
■ FDA Black Box Warning
None
| Common Effects | Hypotension low blood pressure |
| Serious Effects |
Pregnancy (second and third trimesters)Hypersensitivity to telmisartan, amlodipine, or any dihydropyridineHistory of angioedema with ARBs or ACE inhibitorsSevere hepatic impairment (Child-Pugh C)Obstructive biliary disease or cholestasisCardiogenic shockUnstable hemodynamics (e.g., acute myocardial infarction with left ventricular failure)Concomitant aliskiren in patients with diabetes or renal impairment (GFR <60 mL/min)
| Precautions | Fetal toxicity: Avoid use in pregnancy; discontinue if pregnancy occurs, Hypotension in volume-depleted patients, Monitor renal function, especially in patients with renal artery stenosis, Hepatic impairment: Use caution with dose adjustment, Peripheral edema with amlodipine, Avoid abrupt discontinuation in patients with severe coronary artery disease |
| Food/Dietary |
Loading safety data…
| Breastfeeding | Telmisartan is excreted in small amounts; amlodipine is excreted in breast milk. Use caution due to potential hypotensive effects in infants. Monitor infant for hypotension, fluid retention, and renal effects. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Potential risk based on ARB action; oligohydramnios, fetal renal dysfunction, skull ossification defects. Second/third trimester: Fetal hypotension, anuria, renal failure, oligohydramnios, pulmonary hypoplasia, skeletal deformities, death. (FDA Category D for 2nd/3rd trimester; Category C for 1st). |
| Fetal Monitoring | Monitor blood pressure, renal function (serum creatinine, BUN), electrolytes. Fetal ultrasound for oligohydramnios, renal anatomy, and growth. Amniotic fluid index. |
| Fertility Effects | No specific human data; animal studies show no impairment of fertility with either component. Telmisartan may affect renin-angiotensin system but no clinical evidence of reduced fertility. |
| Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition increasing amlodipine levels. Limit high-potassium foods (bananas, oranges, spinach, salt substitutes) as telmisartan may increase potassium. Maintain low-sodium diet to enhance antihypertensive effect. |
| Clinical Pearls | Combination of telmisartan (ARB) and amlodipine (CCB) provides synergistic BP reduction; preferred in patients with metabolic syndrome due to telmisartan's PPAR-γ agonist effect. Avoid in pregnancy (ARB) and caution with severe aortic stenosis (amlodipine). Monitor serum potassium and renal function; amlodipine may cause peripheral edema, often dose-dependent. Grapefruit juice increases amlodipine levels; avoid coadministration. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily. · Do not stop suddenly without consulting your doctor, as blood pressure may rise. · Avoid grapefruit and grapefruit juice as they can dangerously increase drug levels. · Report any signs of allergic reaction (rash, swelling, difficulty breathing) or severe dizziness. · If you become pregnant, stop the medication and contact your doctor immediately. · Stay hydrated, but avoid potassium supplements or salt substitutes without doctor approval. · Common side effects include ankle swelling, headache, dizziness; notify your doctor if persistent. · This medication does not cure high blood pressure but helps control it; continue other lifestyle measures. |